Logo image of BYL.CA

BAYLIN TECHNOLOGIES INC (BYL.CA) Stock Fundamental Analysis

TSX:BYL - Toronto Stock Exchange - CA0728191051 - Common Stock - Currency: CAD

0.265  -0.02 (-8.62%)

Fundamental Rating

2

BYL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 15 industry peers in the Electronic Equipment, Instruments & Components industry. BYL has a bad profitability rating. Also its financial health evaluation is rather negative. BYL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year BYL has reported negative net income.
BYL had a positive operating cash flow in the past year.
In the past 5 years BYL always reported negative net income.
In multiple years BYL reported negative operating cash flow during the last 5 years.
BYL.CA Yearly Net Income VS EBIT VS OCF VS FCFBYL.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -15.07%, BYL perfoms like the industry average, outperforming 46.67% of the companies in the same industry.
Industry RankSector Rank
ROA -15.07%
ROE N/A
ROIC N/A
ROA(3y)-20.62%
ROA(5y)-29.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BYL.CA Yearly ROA, ROE, ROICBYL.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K

1.3 Margins

Looking at the Gross Margin, with a value of 42.08%, BYL is in line with its industry, outperforming 60.00% of the companies in the same industry.
BYL's Gross Margin has improved in the last couple of years.
BYL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y40.78%
GM growth 5Y2.81%
BYL.CA Yearly Profit, Operating, Gross MarginsBYL.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

1

2. Health

2.1 Basic Checks

BYL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BYL has more shares outstanding
Compared to 5 years ago, BYL has more shares outstanding
BYL has a worse debt/assets ratio than last year.
BYL.CA Yearly Shares OutstandingBYL.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BYL.CA Yearly Total Debt VS Total AssetsBYL.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -4.54, we must say that BYL is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -4.54, BYL is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
BYL has a debt to FCF ratio of 5.56. This is a neutral value as BYL would need 5.56 years to pay back of all of its debts.
The Debt to FCF ratio of BYL (5.56) is better than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 5.56
Altman-Z -4.54
ROIC/WACCN/A
WACC8.77%
BYL.CA Yearly LT Debt VS Equity VS FCFBYL.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M

2.3 Liquidity

BYL has a Current Ratio of 0.80. This is a bad value and indicates that BYL is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of BYL (0.80) is worse than 80.00% of its industry peers.
A Quick Ratio of 0.46 indicates that BYL may have some problems paying its short term obligations.
With a Quick ratio value of 0.46, BYL is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.8
Quick Ratio 0.46
BYL.CA Yearly Current Assets VS Current LiabilitesBYL.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

3

3. Growth

3.1 Past

BYL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 88.98%, which is quite impressive.
Looking at the last year, BYL shows a very negative growth in Revenue. The Revenue has decreased by -41.93% in the last year.
BYL shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.42% yearly.
EPS 1Y (TTM)88.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.05%
Revenue 1Y (TTM)-41.93%
Revenue growth 3Y-6.57%
Revenue growth 5Y-11.42%
Sales Q2Q%-5.92%

3.2 Future

Based on estimates for the next years, BYL will show a very strong growth in Earnings Per Share. The EPS will grow by 27.48% on average per year.
Based on estimates for the next years, BYL will show a small growth in Revenue. The Revenue will grow by 1.73% on average per year.
EPS Next Y25%
EPS Next 2Y27.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-4.32%
Revenue Next 2Y1.73%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BYL.CA Yearly Revenue VS EstimatesBYL.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
BYL.CA Yearly EPS VS EstimatesBYL.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -0.2 -0.4 -0.6 -0.8

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BYL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BYL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BYL.CA Price Earnings VS Forward Price EarningsBYL.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

BYL's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. BYL is cheaper than 73.33% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BYL is valued cheaply inside the industry as 93.33% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 6.99
EV/EBITDA 55.75
BYL.CA Per share dataBYL.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as BYL's earnings are expected to grow with 27.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.48%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BYL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BAYLIN TECHNOLOGIES INC

TSX:BYL (7/11/2025, 7:00:00 PM)

0.265

-0.02 (-8.62%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)05-07 2025-05-07
Earnings (Next)08-05 2025-08-05
Inst Owners0.05%
Inst Owner ChangeN/A
Ins Owners1.88%
Ins Owner ChangeN/A
Market Cap40.16M
Analysts76.67
Price Target0.33 (24.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.33%
PT rev (3m)-13.33%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-100%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-9.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.49
P/FCF 6.99
P/OCF 6.9
P/B N/A
P/tB N/A
EV/EBITDA 55.75
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)0.04
FCFY14.31%
OCF(TTM)0.04
OCFY14.5%
SpS0.54
BVpS-0.07
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.07%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.08%
FCFM 6.97%
ROA(3y)-20.62%
ROA(5y)-29.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y40.78%
GM growth 5Y2.81%
F-Score4
Asset Turnover1.74
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 5.56
Debt/EBITDA 33.09
Cap/Depr 2.93%
Cap/Sales 0.09%
Interest Coverage N/A
Cash Conversion 620.23%
Profit Quality N/A
Current Ratio 0.8
Quick Ratio 0.46
Altman-Z -4.54
F-Score4
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)11.25%
Cap/Depr(5y)21.99%
Cap/Sales(3y)0.89%
Cap/Sales(5y)2.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.05%
EPS Next Y25%
EPS Next 2Y27.48%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-41.93%
Revenue growth 3Y-6.57%
Revenue growth 5Y-11.42%
Sales Q2Q%-5.92%
Revenue Next Year-4.32%
Revenue Next 2Y1.73%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y88.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year310.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y470.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1768.77%
OCF growth 3YN/A
OCF growth 5YN/A